LGVNLongeveron Inc.

$18M

Q4 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$1M-36.0% YoY

Gross Profit

$529,03244.8% margin

Operating Income

-$1M-117.2% margin

Net Income

-$1M-114.9% margin

EPS (Diluted)

$-0.79

QoQ Revenue Growth

-36.7%

Cash Flow

Operating Cash Flow

-$505,000

Free Cash Flow

-$492,000

Stock-Based Comp.

$3,000

Balance Sheet

Total Assets

$9M

Total Liabilities

$7M

Stockholders' Equity

$2M

Cash & Equivalents

$816,000

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1M	$2M	-36.0%
Gross Profit	$529,032	$607,233	-12.9%
Operating Income	-$1M	-$474,035	-191.8%
Net Income	-$1M	-$473,695	-186.3%

LGVN Q4 2020 Earnings — Longeveron Inc. Revenue & Financial Results | Market Cap Arena